CNBCGE Healthcare IPO this year 'looks unlikely' after Danaher deal, CEO Culp saysFeb 25, 2019more_vert
The Wall Street JournalGE to Sell Its Biotech Business to Danaher for $21 BillionFeb 25, 2019Thomas GrytaBy Thomas Grytamore_vert
CNBCGE shares surge after Danaher agrees to buy biopharma business for $21.4 billionFeb 25, 2019Michael SheetzBy Michael Sheetzmore_vert